Respiratory fluoroquinolones, like levofloxacin, play a pivotal role in the treatment of patients who have failed initial antibiotic treatment for chronic bronchitis
Older patients are at increased risk for resistant pathogens during epidsodes of acute exacerbation of chronic bronchitis (AECB). A review by staff in the Division of Pulmonary and Critical Care Medicine, Northern California Health Care System, Sacramento, points out that many AECB guidelines which are stratified according to risk factors recommend oral respiratory fluoroquinolones, like levofloxacin, gemifloxacin and moxifloxacin, as second-line but pivotal treatments especially in the case of patients who have failed to respond to their initial antibiotic treatment for simple CB.
Expert Rev Respir Med. 2009 Oct;3(5):539-48.
Source : http://www.ncbi.nlm.nih.gov/pubmed/20477342?dopt=Abstract